Hamilton Thorne Launches New Corporate Website
BEVERLY, Mass. and TORONTO, June 28, 2018 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced that it is launching a new website (www.hamiltonthorne.ltd) focused on investor-oriented resources.
“Our goal with this new website is to provide one central location for interested investors, business partners and the general public to learn about Hamilton Thorne’s dynamic business and our growing family of brands,” stated David Wolf, President and Chief Executive Officer. “The new website incorporates a look and feel that matches our updated corporate branding and provides easy access to financial information, press releases and other important news surrounding our leading technologies, brands and product lines.”
The Hamilton Thorne, Inc. (www.hamiltonthorne.com), Gynemed (www.gynemed.de) and Embryotech Laboratories (www.embryotech.com) brands will continue to maintain their separate websites focused on the needs of their customers and the markets that they serve.
About Hamilton Thorne Ltd.(www.hamiltonthorne.ltd)
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
For more information, please contact:
David Wolf, President & CEO
Hamilton Thorne Ltd.
978-921-2050
ir@hamiltonthorne.com
Michael Bruns, CFO
Hamilton Thorne Ltd.
978-921-2050
ir@hamiltonthorne.com
Glen Akselrod
Bristol Investor Relations
416-737-4467
glen@bristolir.com
© 2018 GlobeNewswire, Inc. All Rights Reserved.
Moderna (Nasdaq: MRNA) Announces Publication in The New England Journal of Medicine of Interim Results From Older Adult Age Cohorts in Phase 1 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)
